1 / 44

If I had an acute coronary syndrome, which antiplatelet agent would I prefer?

If I had an acute coronary syndrome, which antiplatelet agent would I prefer?. Giuseppe Biondi Zoccai, MD, FSICI-GISE Division of Cardiology University of Modena and Reggio Emilia gbiondizoccai@gmail.com. LEARNING GOALS. SCOPE OF THE PROBLEM MENU A LA CARTE OR TABLE D’HOTE? MY OWN RECIPE.

nibaw
Download Presentation

If I had an acute coronary syndrome, which antiplatelet agent would I prefer?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. If I had an acute coronary syndrome, which antiplatelet agent would I prefer? Giuseppe Biondi Zoccai, MD, FSICI-GISE Division of Cardiology University of Modena and Reggio Emilia gbiondizoccai@gmail.com

  2. LEARNING GOALS • SCOPE OF THE PROBLEM • MENU A LA CARTE OR TABLE D’HOTE? • MY OWN RECIPE

  3. LEARNING GOALS • SCOPE OF THE PROBLEM • MENU A LA CARTE OR TABLE D’HOTE? • MY OWN RECIPE

  4. ACUTE CORONARY SYNDROMES Plaque rupture Old terms Stable angina Unstable angina Q-MI Non-Q MI New terms STEMI Atherothrombosis UA/NSTEMI Days Weeks Minutes Hours Antithrombotic therapy & (selectively) invasive management Reperfusion (thrombolysis and/or PTCA)

  5. SCOPE OF THE PROBLEM Bleeding Peri-procedural complications Thrombotic events Myocardial ischemia

  6. SCOPE OF THE PROBLEM Bleeding Peri-procedural complications Thrombotic events Myocardial ischemia

  7. SCOPE OF THE PROBLEM

  8. SCOPE OF THE PROBLEM: AMI Capewell et al, Heart 2006 Capewell et al, Heart 2006

  9. SCOPE OF THE PROBLEM: UNSTABLE ANGINA Capewell et al, Heart 2006 Capewell et al, Heart 2006

  10. PATHWAYS TO THROMBOSIS * * * * Myers, BUMC Proceedings 2005 Myers, BUMC Proceedings 2005

  11. MULTIPLE VULNERABLE CORONARY PLAQUES IN PATIENTS WITH AMI Asakura et al, J Am Coll Cardiol 2001 Asakura et al, J Am Coll Cardiol 2001

  12. MULTIPLE RUPTURED CORONARY PLAQUES IN PATIENTS WITH ACS

  13. ENDOTHELIALIZATION OF STENT STRUTS SES BMS Guagliumi et al, Ital Heart J 2003 Guagliumi et al, Ital Heart J 2003

  14. ON TOP OF THIS:VARIABILITY IN RESPONSE TO ANTITHROMBOTIC THERAPY

  15. VARIABILITY IN RESPONSE Change in ADP-Induced Platelet Aggregation 75 mg chronic dosing Maximal aggregation 5 µmol/L ADP (%) following 600 mg loading dose 100 N=1001 N=544 80 60 Number of Patients 40 20 0 0 2 4 6 8 10 Time from loading dose to cath (h) Relative change in aggregation Serebruany et al, J Am Coll Cardiol 2005 Hochholzer et al, Circulation 2005

  16. GENETIC VARIABILITY IN RISK OF STENT THROMBOSIS Mega et al, New Engl J Med 2009

  17. FAILING STENTS: THROMBOSIS VS RESTENOSIS Schuchman, New Engl J Med 2006

  18. MECHANISMS OF THROMBOSIS: VIRCHOW'S TRIAD BLOOD FLOW VESSEL

  19. MECHANISMS OF STENT THROMBOSIS PATIENT FACTORS LESION FACTORS PROCEDURAL & MEDICAL RX FACTORS

  20. PREDICTING THROMBOSIS ACCORDING TO DIABETES Machecourt et al, J Am Coll Cardiol 2009

  21. PREDICTING THROMBOSIS ACCORDING TO STENT LENGTH Moreno et al, J Am Coll Cardiol 2005

  22. PREDICTORS OF STENT THROMBOSIS AFTER ACS OR Van Werkum et al, J Am Coll Cardiol 2009

  23. LEARNING GOALS • SCOPE OF THE PROBLEM • MENU A LA CARTE OR TABLE D’HOTE? • MY OWN RECIPE

  24. ASPIRIN

  25. ASPIRIN IN UNSTABLE ANGINA 0.25 Placebo 0.20 Risk ratio after 1 year 0.5295% Cl 0.37–0.72 (P=0.0001) 0.15 Probability of death or MI 0.10 ASA 75 mg 0.05 0.00 0 3 6 9 12 Months Wallentin et al, JACC 1991

  26. CLOPIDOGREL

  27. PCI-CURE 12.6% 1.9% ARR 31% RRR P=0.002 N=2,658 0.15 Placebo Clopidogrel 8.8% 0.10 Cumulative hazard rates for CV death/MI 0.05 0.0 0 100 200 300 400 10 40 Days of follow-up a b a = median time PCI (10 days) b = 30 days after median time of PCI Mehta et al, Lancet 2001

  28. IMPACT OF ANTIPLATELET THERAPY INTENSITY 30-day results of the CURRENT-OASIS 7 Trial Mehta et al, Lancet 2010

  29. SUMMARY OF EVIDENCE ON CLOPIDOGREL LOADING Lotrionte et al, Am J Cardio 2007;100:1199-1206

  30. ABCIXIMAB

  31. BENEFITS OF ABCIXIMAB IN ACS PATIENTS PRETREATED WITH 600 MG CLOPIDOGREL 600 mg clopidogrel 500 mg ASA >2 h before PCI * *Death/MI/urgent TVR Kastrati et al, JAMA 2006

  32. PRASUGREL

  33. THE TRITON-TIMI 38 2.31% 2 CLOPIDOGREL 1.5 % of subjects having DES thrombosis Hazard ratio 0.36 [0.22-0.58] P<0.0001 0.84% 1 PRASUGREL 0.5 0 Days 0 50 100 150 200 250 300 350 400 450

  34. THE TRITON-TIMI 38 Wiviott et al, Lancet 2008;371:1353-63

  35. TICAGRELOR

  36. THE PLATO TRIAL Wallentin et al, NEJM 2009

  37. THE PLATO TRIAL Wallentin et al, NEJM 2009

  38. THE PLATO TRIAL Wallentin et al, NEJM 2009

  39. WHEN IS MUCH TOO MUCH?

  40. LEARNING GOALS • SCOPE OF THE PROBLEM • MENU A LA CARTE OR TABLE D’HOTE? • MY OWN RECIPE

  41. INDIRECT COMPARISON OF PRASUGREL VS. TICAGRELOR Funnel plots comparing prasugrel vs. ticagrelor for the risk of key clinical events. Odds ratios (OR) <1.0 favor prasugrel, whereas odds ratios>1.0 favor ticagrelor.

  42. Intra-hospital transfer ER Out-of-hospital EMS Appraisal of thrombotic and bleeding risks – aspirin unless bleeding risk prohibitive  thrombotic risk  bleeding risk  thrombotic risk  bleeding risk  thrombotic risk  bleeding risk  thrombotic risk  bleeding risk Clopidogrel or Ticagrelor Prasugrel or Ticagrelor Wait-and-see Wait-and-see Coronary angiography CABG Medical Rx pPCI with BMS pPCI with DES Clopidogrel, Prasugrel or Ticagrelor Clopidogrel, Prasugrel or Ticagrelor Clopidogrel or Ticagrelor Ticagrelor

  43. TAKE HOME MESSAGE THROMBOSIS BLEEDING

  44. ThankyouforyourattentionForanycorrespondence: gbiondizoccai@gmail.comForthese and furtherslides on thesetopicsfeel free tovisit the metcardio.org website:http://www.metcardio.org/slides.html

More Related